Liquidia Corporation (LQDA)
NASDAQ: LQDA
· Real-Time Price · USD
14.01
0.04 (0.29%)
At close: May 01, 2025, 3:56 PM
0.29% (1D)
| Bid | 13.4 |
| Market Cap | 1.19B |
| Revenue (ttm) | 14M |
| Net Income (ttm) | -130.39M |
| EPS (ttm) | -1.66 |
| PE Ratio (ttm) | -8.44 |
| Forward PE | -38.85 |
| Analyst | Buy |
| Ask | 14.8 |
| Volume | 500,128 |
| Avg. Volume (20D) | 1,014,460 |
| Open | 13.98 |
| Previous Close | 13.97 |
| Day's Range | 13.81 - 14.33 |
| 52-Week Range | 8.26 - 16.81 |
| Beta | 0.22 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisvill...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2018
Employees 170
Stock Exchange NASDAQ
Ticker Symbol LQDA
Website https://www.liquidia.com
Analyst Forecast
According to 8 analyst ratings, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 92.79% from the latest price.
Stock ForecastsNext Earnings Release
Liquidia Corporation is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+11.17%
Liquidia Corp shares are trading higher after the ...
Unlock content with
Pro Subscription
7 months ago
+14.04%
Liquidia shares are trading higher after the company announced it raised $67.5 million from the common stock financing of 6,460,674 shares at $8.90 per share.
